Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M500523200 on January 28, 2005

J. Biol. Chem., Vol. 280, Issue 15, 14918-14922, April 15, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/15/14918    most recent
M500523200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lloyd, D. B.
Right arrow Articles by Thompson, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lloyd, D. B.
Right arrow Articles by Thompson, J. F.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Cholesteryl Ester Transfer Protein Variants Have Differential Stability but Uniform Inhibition by Torcetrapib*

David B. Lloyd{ddagger}, Maruja E. Lira{ddagger}, Linda S. Wood{ddagger}, L. Kathryn Durham§, Thomas B. Freeman¶, Gregory M. Preston¶, Xiayang Qiu||, Eliot Sugarman**, Peter Bonnette**, Anthony Lanzetti||, Patrice M. Milos{ddagger}, and John F. Thompson{ddagger}{ddagger}{ddagger}

From the Departments of {ddagger}Discovery Pharmacogenomics, §Clinical Biostatistics, Translational Biomarkers, ||Protein Expression and Structure, and **Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton, Connecticut 06340

Cholesteryl ester transfer protein (CETP) is an important modulator of high density lipoprotein cholesterol in humans and thus considered to be a therapeutic target for preventing cardiovascular disease. The gene encoding CETP has been shown to be highly variable, with multiple single nucleotide polymorphisms responsible for altering both its transcription and sequence. Examining nine missense variants of CETP, we found some had significant associations with CETP mass and high density lipoprotein cholesterol levels. Two variants, Pro-373 and Gln-451, appear to be more stable in vivo, an observation mirrored by partial proteolysis studies performed in vitro. Because these naturally occurring variant proteins are potentially present in clinical populations that will be treated with CETP inhibitors, all commonly occurring haplotypes were tested to determine whether the proteins they encode could be inhibited by torcetrapib, a compound currently in clinical trials in combination with atorvastatin. Torcetrapib behaved similarly with all variants, with no significant differences in inhibition.


Received for publication, January 14, 2005

* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

{ddagger}{ddagger} To whom correspondence should be addressed: MS8118D-3069, Eastern Point Rd., Pfizer Global Research and Development, Groton, CT 06340. Tel.: 860-441-5139; Fax: 860-441-0436; E-mail: john.f.thompson{at}pfizer.com.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Lipid Res.Home page
M. E. Lira, A. K. Loomis, S. A. Paciga, D. B. Lloyd, and J. F. Thompson
Expression of CETP and of splice variants induces the same level of ER stress despite secretion efficiency differences
J. Lipid Res., September 1, 2008; 49(9): 1955 - 1962.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
A. Thompson, E. Di Angelantonio, N. Sarwar, S. Erqou, D. Saleheen, R. P. F. Dullaart, B. Keavney, Z. Ye, and J. Danesh
Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk
JAMA, June 18, 2008; 299(23): 2777 - 2788.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
L. A. Morehouse, E. D. Sugarman, P.-A. Bourassa, T. M. Sand, F. Zimetti, F. Gao, G. H. Rothblat, and A. J. Milici
Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits
J. Lipid Res., June 1, 2007; 48(6): 1263 - 1272.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
J. F. Thompson, L. S. Wood, E. H. Pickering, B. DeChairo, and C. L. Hyde
High-density genotyping and functional SNP localization in the CETP gene
J. Lipid Res., February 1, 2007; 48(2): 434 - 443.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Gauthier, P. Lau, X. Zha, R. Milne, and R. McPherson
Cholesteryl Ester Transfer Protein Directly Mediates Selective Uptake of High Density Lipoprotein Cholesteryl Esters by the Liver
Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2177 - 2184.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement